Literature DB >> 305953

Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid.

S Nousia-Arvanitakis, C Arvanitakis, N Desai, N J Greenberger.   

Abstract

The synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid is specifically cleaved by chymotrypsin to Bz-Ty and PABA. The liberated PABA is absorbed and excreted in the urine. Accordingly, PABA recovery reflects intraluminal chymotrypsin activity and is an index of exocrine pancreatic function. This test was evaluated in 24 patients with cystic fibrosis to determine its role in the diagnosis of exocrine pancreatic insufficiency. Cumulative percent PABA recovery in six hours was significantly lower in CF patients compared with the control group. No overlap was noted between the two groups. There was good correlation between PABA recovery, fecal chymotrypsin activity, and coefficient of fat absorption. These findings indicate that PABA recovery is significantly reduced in patients with CF and steatorrhea and may prove a practical and reliable test of pancreatic insufficiency.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305953     DOI: 10.1016/s0022-3476(78)80139-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  BT-PABA test with plasma PABA measurements: evaluation of sensitivity and specificity.

Authors:  J C Delchier; J C Soule
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

2.  In vitro and in vivo analysis of the PABA test compared with the Lundh test--influence of intraluminal pH.

Authors:  F J Hoek; G T Sanders; A Teunen; G N Tijtgat
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

Review 3.  Exocrine pancreatic function tests.

Authors:  P G Lankisch
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

4.  Improved sensitivity of the BTPABA pancreatic function test in animals with meals of raw egg white.

Authors:  A R Imondi; R L Wolgemuth
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

5.  Comparison of the oral (PABA) pancreatic function test, the secretin-pancreozymin test and endoscopic retrograde pancreatography in chronic alcohol induced pancreatitis.

Authors:  A S Mee; A H Girdwood; E Walker; N H Gilinsky; R E Kottler; I N Marks
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

6.  Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.

Authors:  G Koren; Z Weizman; G Forstner; S M MacLeod; P R Durie
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

7.  BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared.

Authors:  S Bellentani; A Grisendi; M Rinaldi; P Bertolani; G Costa; M Agostini; G Mastella; F Balli; F Manenti
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

8.  The development of the chymotryptic activity during postnatal life using the bentiromide test.

Authors:  Y Bujanover; A Harel; R Geter; H Blau; J Yahav; Z Spirer
Journal:  Int J Pancreatol       Date:  1988 Jan-Feb

9.  Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by use of fluorescein dilaurate test.

Authors:  J G Cumming; J S Forsyth; E J Boyd; G J Frost; A Cuschieri
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

10.  Diagnostic and therapeutic applications of bentiromide screening test for exocrine pancreatic insufficiency in patients with cystic fibrosis. Comparison with other tests of exocrine pancreatic disease.

Authors:  V S Hubbard; R O Wolf; L A Lester; A C Egge
Journal:  Dig Dis Sci       Date:  1984-10       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.